Furthermore, recent publications provide proof of concept that chemical inhibition of ATGL might be a good therapeutic strategy for treating obesity and related metabolic diseases as mice treated with atglistatin showed reduced adipose tissue lipolysis, weight gain, and insulin resistance (60, 65, 66, 67). The gene discussed is PNPLA2; the disease is metabolic disease.